Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic eraOncology Original Research Published on 2024-04-232024-09-05 Journal: Frontiers in Oncology [Category] update2024, [키워드] COVID-19 diffuse large B-cell lymphoma elderly Hypogammaglobulinemia Immunochemotherapy [DOI] 10.3389/fonc.2024.1380492 PMC 바로가기 [Article Type] Oncology Original Research
Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN surveyarticle Published on 2023-04-042024-09-02 Journal: Pediatric Nephrology (Berlin, Germany) [Category] 대상포진, [키워드] children Hypogammaglobulinemia nephrotic syndrome rituximab [DOI] 10.1007/s00467-023-05913-1 PMC 바로가기 [Article Type] article
Infectious Complications of Chimeric Antigen Receptor (CAR) T-Cell TherapiesArticle Published on 2023-03-062024-09-04 Journal: Seminars in hematology [Category] 대상포진, [키워드] chimeric antigen receptor (CAR) Cytokine release syndrome Hypogammaglobulinemia neutropenia opportunistic infection [DOI] 10.1053/j.seminhematol.2023.02.003 PMC 바로가기 [Article Type] Article
Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experienceIm - Original Published on 2023-02-242024-09-04 Journal: Internal and Emergency Medicine [Category] 대상포진, [키워드] adverse events Hypogammaglobulinemia infections Infusion-related reactions Interchangeability rituximab [DOI] 10.1007/s11739-023-03222-x PMC 바로가기 [Article Type] Im - Original
SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patientsArticle Published on 2022-12-222023-07-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), [키워드] B cells common variable immunodeficiency Hypogammaglobulinemia immune memory primary antibody deficiency SARS-CoV-2 specific antibody deficiency vaccination [DOI] 10.3389/fimmu.2022.1033770 PMC 바로가기
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UKArticle Published on 2022-09-292022-11-15 Journal: Clinical and experimental immunology [Category] SARS, 진단, [키워드] access age anti-SARS-CoV-2 baseline co-morbidity Cohort Combination convalescent plasma COVID-19 COVID-19 treatment CVID demonstrated Dexamethasone died Fatality rate General population high risk hospital Hypogammaglobulinemia IFR immunodeficiency inborn errors of immunity increased the risk Increasing individual Infection Lymphocyte count lymphopenia monotherapy Mortality network outcome overall mortality Patient PID Primary immunodeficiencies receiving REGN-CoV2 Remdesivir reported risk factor SARS-CoV-2 SARS-COV-2 infection secondary immunodeficiencies. therapeutic Tocilizumab Treatment United Kingdom [DOI] 10.1093/cei/uxac008 PMC 바로가기
Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiencyArticle Published on 2022-09-142022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] activity Adverse reaction analyzed Anti-SARS-CoV-2 S antibody Antibody Response Autoimmune Autoimmune diseases B-lymphocytes Cell Cohort cohort of patient comparable Course COVID-19 COVID-19 vaccination CVID deficiency detect Disease activity dysfunction effective Efficacy and safety Elecsy flow cytometry healthy control humoral humoral immune response Hypogammaglobulinemia IFN-gamma immune system Immunity immunization immunoassay immunodeficiency immunoglobulin replacement therapy in healthy individuals increased risk individual Interferon-gamma lymphocyte neutralization Patient Phenotyping pneumococcal provide reactogenicity receptor Safe SARS-COV-2 infection selective Seven subjects Support syndrome T cell response T-lymphocites the disease triggering underlying disease vaccination vaccine response Vero E6 Virus neutralization was performed well X-linked agammaglobulinemia XLA [DOI] 10.3389/fimmu.2022.974987 PMC 바로가기
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and COVID-19: The Clinical Course and Prognosis of 15 Patients From a Tertiary Care CenterArticle Published on 2022-09-012022-11-15 Journal: Journal of clinical rheumatology : practical reports on rheumatic & [Category] 바이오마커, 진단, [키워드] age alveolar center clinical Clinical finding coronavirus disease COVID-19 COVID-19 pandemic cytoplasmic Deceased Diagnosis died Disease activity evaluate Factor glomerular filtration rate glucocorticoid hemorrhage Hospital admission Hospitalized Hypogammaglobulinemia IgG incidence rates Inpatient intensive care Laboratory medical records Mortality organ damage outcome Patient Prognosis renal severe pneumonia symptomatic Tertiary the disease the patient treatment history Vasculitis were recorded were used with COVID-19 [DOI] 10.1097/RHU.0000000000001855 PMC 바로가기
The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study혈액 질환에서 mRNA COVID-19 백신의 체액 반응: HEMVACO 연구Article Published on 2022-08-012022-09-12 Journal: Infectious diseases now [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] analyzed Anti-CD20 monoclonal antibody anti-CD20 therapy anti-SARS-CoV-2 anti-SARS-CoV-2 vaccination Antibody titer booster immunization Cohort COVID-19 vaccine defined dose evaluated Factor Hematologic diseases hematological high-risk patient humoral Hypogammaglobulinemia IgG IgG titer lymphopenia median titer monoclonal mRNA mRNA-1273 vaccine of BNT162b2 Patient patients performed positive Registered SARS-CoV-2 SARS-CoV-2 vaccine second dose Seroconversion serology the SARS-CoV-2 therapy Treatment two group Vaccine vaccine dose vaccine response was obtained were measured [DOI] 10.1016/j.idnow.2022.05.008 PMC 바로가기 [Article Type] Article
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy Reviews Published on 2022-07-152022-10-05 Journal: Bone marrow transplantation [Category] 치료제, [키워드] CAR CD19 Cell chimeric antigen receptor clinically complications Cytokine release syndrome disease Evidence Factor hematologic Hypogammaglobulinemia immune immune function incidence increasingly Infection less lymphoid malignancies Patient patients Prophylaxis recipient risk factor Side effect standard treatment T-cell T-cells therapy Treatment undergo Vaccination strategy [DOI] 10.1038/s41409-022-01756-w [Article Type] Reviews